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The ABO blood group system is the most important blood type system in human trans-
fusion medicine. Here, we explore the specificity of antibody recognition toward ABO
blood group antigens using computational modeling and biolayer interferometry. Auto-
mated docking and molecular dynamics simulations were used to explore the origin of the
specificity of an anti-blood group A antibody variable fragment (Fv AC1001). The analysis
predicts a number of Fv-antigen interactions that contribute to affinity, including a hydrogen
bond between a HisL49 and the carbonyl moiety of the GalNAc in antigen A. This interac-
tion was consistent with the dependence of affinity on pH, as measured experimentally; at
lower pH there is an increase in binding affinity. Binding energy calculations provide unique
insight into the origin of interaction energies at a per-residue level in both the scFv and the
trisaccharide antigen. The calculations indicate that while the antibody can accommodate
both blood group A and B antigens in its combining site, the A antigen is preferred by
4 kcal/mol, consistent with the lack of binding observed for the B antigen.
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INTRODUCTION
Since its discovery in 1900 (1), the ABO blood group system
has played a crucial role in defining human blood and tissue
compatibility. The blood type of an individual indicates the pres-
ence or absence of relevant antigens and antibodies. The three
blood types share a core oligosaccharide antigen (H), and based
on the glycosyl transferases inherited, different antigens are syn-
thesized (2–4); type A transferase adds a terminal non-reducing
N -acetylgalactosamine (GalNAc) residue; type B transferase adds
galactose (Gal), whereas individuals with blood group O retain the
unmodified H antigen. During the first years of life, the immune
system forms antibodies upon exposure to non-self antigens from
various exogenous factors. Thus an A-type individual will have cir-
culating antibodies specific for the B-antigen, and vice-versa. The
high degree of specificity is notable given that the only difference
between the structures of the A- and B-antigens is the replace-
ment of an acetamido moiety (in A) with a hydroxyl group (in B).
Because of the presence of circulating antibodies, a mismatched
blood transfusion or organ transplant can lead to hyperacute
immune response and death (5, 6). Additionally, under certain
circumstances, incompatibilities in blood groups between mother
and child can trigger the mother’s immune system to produce
antibodies against the fetus, causing hemolytic disease (7).
Alterations in the structures of the ABO antigens often occur
during carcinogenesis and therefore they have also been consid-
ered tumor markers (8, 9). Recently, strong correlations have been
established between the presence of particular ABO and Lewis
antigens and susceptibility to infectious diseases, such as Heli-
cobacter pylori, norovirus, and cholera (10), wherein the blood
group antigens can be exploited as receptors for bacterial and
viral adhesion. Conversely, it has been suggested that endogenous
anti-blood group antibodies can recognize blood-group-like car-
bohydrate antigens on pathogen surfaces, conferring protection
against infection (11).
Despite their clinical importance, relatively little is known
about the structural basis for these highly specific antibodies–
antigen interactions. Although X-ray crystallography has been
used to characterize antibody–carbohydrate complexes, the gen-
erally enhanced flexibility and conformational heterogeneity of
oligosaccharides detracts from the ability to generate co-crystals
(12). Additionally, anti-carbohydrate antibodies bind to their anti-
gens with an affinity that is 3–5 orders of magnitude lower than
typical antibodies that bind to protein or peptide antigens. Dif-
ficulties in generating 3D structures for carbohydrate–antibody
complexes have led to the increasing use of theoretical structure
prediction methods (13, 14), which, while convenient, are prone to
predicting false positives due to inaccuracies in pose scoring func-
tions (15) and to the omission of carbohydrate conformational
preferences (16).
In this study, we examined the structural origin of the anti-
genicity (the specificity and affinity) of a monoclonal antibody
raised against blood group A (BGA) antigen, for which an apo
structure of the single-chain variable fragment (scFv AC1001)
has been reported (17). The specificity data from screening two
independent glycan arrays [Consortium for Functional Glycomics
(v4.0, request ID: 1808) and from the group of Jeff Gildersleeve]
confirmed that the scFv displayed no detectable binding to any
B-antigens and only bound to BGA-containing glycans. To pro-
vide a structural interpretation for the specificity of AC1001 for
BGA over blood groups H (BGH) and B (BGB), we generated a
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3D model of the immune complex using molecular docking and
refined it by molecular dynamics (MD) simulation. Despite its
limitations, molecular docking, with or without additional exper-
imental constraints, such as from NMR data, is often the only
approach that may be employed to generate the structure of a
ligand–protein complex, in the absence of direct crystallographic
data. To enhance the success rate, a recent carbohydrate conforma-
tional energy function (16) was employed with AutoDock VINA
(18), which quantifies the conformational preferences of oligosac-
charides based on their glycosidic torsion angles. MD simulations
(50 ns) were subsequently performed to ensure that the docked
complexes were stable under physically realistic conditions, and
in that event, the MD data were employed in binding free energy
calculations. A particular advantage of MD-based energy calcula-
tions is that they provide statistically converged values that may
be partitioned into contributions from individual residues in the
protein and ligand (19).
MATERIALS AND METHODS
CLONING, EXPRESSION, AND PURIFICATION OF scFv
An scFv gene containing a short linker (RADAA) and the Leu
103H Val mutation (17), with a His6 tag, was assembled by PCR
and cloned into the phagemid pSK4. The construct was main-
tained in Escherichia coli TG1 cells. Cells from positive clones, as
judged by DNA sequence analysis, were grown in minimal media,
induced, and subjected to periplasmic extraction. The scFv dimer
was purified from the extract by Ni2+ immobilized metal affinity
chromatography, by elution with an imidazole gradient.
BIOLAYER INTERFEROMETRY
Affinity measurements were performed on a biolayer interferom-
eter (Octet Red96, ForteBio). Data were processed using the Data
Acquisition and Analysis 8.0 software (ForteBio), and kinetic bind-
ing constants were determined from a 1:1 binding model using
the OriginPro software (OriginLab). The scFv was immobilized
on an amine reactive second-generation (AR2G) biosensor (Lot
No. 1311212, ForteBio). The BGA trisaccharide was analyzed as
the conjugate to bovine serum albumin (BSA–BGA) and was dis-
solved in an analysis buffer containing 10 mM HEPES, 150 mM
NaCl, 3.4 mM EDTA, and 0.005% Tween 20 at a range of pH values
(5, 5.5, 6, 6.5, and 7). A BSA–LeX trisaccharide conjugate (Prod.
No. NGP0302, V-Labs, Inc.) and BSA (Prod. No. 23209, Pierce
Thermo Scientific, Rockford, IL, USA) were used as negative con-
trols. Details of the biolayer interferometry (BLI) conditions are
provided in Supplemental Material.
AUTOMATED DOCKING
Docking was performed using AutoDock VINA (18) with 20
docked poses generated for each experiment. The protein and the
ligand files were prepared using Autodock tools (ADT) (20) with
Gassteiger (21) partial atomic charges assigned to both the pro-
tein and ligand residues. The crystal structure of the scFv (PDB
ID: 1JV5) was employed, together with a 3D structure of BGA
obtained from the GLYCAM-Web server (www.glycam.org). Crys-
tal waters were removed prior to docking and hydrogen atoms
were added to the protein using ADT, whereas hydrogen atoms
in the ligand were assigned from the GLYCAM residue tem-
plates. The glycosidic φ and ϕ torsion angles were allowed to
be flexible during docking, as were all the hydroxyl groups. The
protein was maintained rigid. The docking grid box (dimen-
sions: 26.25 Å× 26.25 Å× 37.5 Å) was centered relative to the
complementarity determining regions (CDRs) of the antibody as
described previously (16). For the mutational-docking approach,
TrpH100 was mutated to Ala by deleting the side-chain atoms of the
Trp residue in the crystal structure, followed by processing with the
tleap module in AMBER (22). AlaH100 was reverted back to Trp by
restoring the crystal coordinates of the side chain of TrpH100. The
docked poses from the mutational approach were filtered based
on the clashes with the reverted Trp. Poses in which the clashes
could not be eliminated by implicit energy minimization (details
are in the “MD simulations” section) were rejected. Ligand con-
formations of all the docked poses from both the flexible and
mutational-docking approaches were scored using the recently
reported carbohydrate intrinsic (CHI) energy scoring function
(16). Any conformations with total CHI-energies >5 kcal/mol
were rejected. The BGB complex was generated directly from that
generated for BGA by simple replacement of the NAc group by an
OH group.
MD SIMULATIONS
All the MD simulations were performed with the GPU implemen-
tation of the pmed code, pmed.cud_SPDP (23), from AMBER12
(22). The calculations employed the ff99SSB (24) parameters for
the protein and the GLYCAM06h (25) parameters for the carbo-
hydrate. For the BGA, BGB–scFv complex simulations, an implicit
solvent energy minimization (5000 steps of steepest descent fol-
lowed by 5000 steps of conjugate gradient), were performed to
optimize the side-chain positions of the reverted Trp residue.
During this minimization, the backbone atoms of the framework
regions were restrained with a 5 kcal/mol Å2 while the CDRs and
the ligand were allowed to be flexible. The systems were then sol-
vated in a cubic water box [120 Å per side, with a TIP3P water
(26)]. Each system was energy minimized using explicit solvent
(10,000 steps of steepest descent, 10,000 steps of conjugate gradi-
ent). During this energy minimization, the protein residues were
restrained with a force constant of 100 kcal/mol Å2 allowing only
the solvent and ligand to relax. This minimization was followed
by heating from 5 to 300 K over the course of 50 ps at constant
volume. Production MD simulations were performed for 50 ns
at constant pressure (NPT ensemble) with the temperature held
constant at 300 K using a Langevin thermostat. During the heat-
ing and the production MD, the backbone atoms of the protein
were restrained with a force constant of 5 kcal/mol Å2, with the
protein side chains and ligand atoms allowed to be flexible. The
backbone atoms were restrained in order to ensure that the pro-
tein fold remained stable during the course of the simulation. For
the BGA trisaccharide MD simulation, the system was solvated
in a cubic water box (120 Å per side, with a TIP3P water) and
energy minimized using explicit solvent (5000 steps of steepest
descent, 5000 steps of conjugate gradient). This was followed by
heating from 5 to 300 K for a period of 50 ps at constant vol-
ume. Production MD simulations were performed for 50 ns at
constant pressure (NPT). During the minimization, heating, and
production MD simulations, there were no restraints placed on
the trisaccharide. For both BGA, BGB–scFv complexes and BGA
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trisaccharide simulations, all covalent bonds involving hydrogen
atoms were constrained using the SHAKE (27) algorithm, allowing
a time step of 2 fs. A non-bonded cut-off of 8 Å was used and long-
range electrostatics were employed using the particle mesh Ewald
(PME) method (28). Snapshots were collected at 1 ps intervals for
subsequent analysis.
ANALYSIS
The stability of the complexes was assessed by monitoring the
root-mean-squared-displacement (RMSD) of the ligand position,
the glycosidic torsion angles, the ring conformations, and the
protein–ligand hydrogen bonds. All these values except for the
ring conformation analysis were generated using the ptraj module
of AMBERTOOLS 12 (29). Ligand RMSD values were calculated
for the ring atoms, relative to the first time step of the simula-
tion. Hydrogen bond interactions between the protein and the
ligand were measured with distance and angle cut-off values of
3.5 Å and 120°, respectively. The ring conformations of each indi-
vidual residue in the ligand during the course of simulation were
analyzed using the recently reported BFMP method (Makeneni
et al., submitted). Binding free energies were calculated with the
MM-GBSA (30, 31) module in AMBERTOOLS12. All the water
molecules were removed prior to the MM-GBSA calculation, and
desolvation free energies were approximated using the generalized
born implicit solvation model (igb= 2) (32).
RESULTS AND DISCUSSION
DOCKING ANALYSIS
In preliminary experiments, docking to the rigid scFv structure
yielded complexes that failed to remain stable during subse-
quent 10 ns MD simulations (Table S1 in Supplementary Mate-
rial). The spontaneous dissociation of the complex during MD
simulation suggested that the docking had failed to detect the
correct, high affinity, pose (33). Upon inspection of the MD
data, it was observed that light chain residue His49 (HisL49)
forms a stacking interaction with heavy chain residue Trp100
(TrpH100), which occupies a large volume of the presumed bind-
ing site, potentially preventing deeper penetration of the ligand
(Figure 1).
As Trp residues can also form stacking interactions with the
apolar face of monosaccharides in antibody complexes (34), we
hypothesized that the trisaccharide ligand might compete for for-
mation of such an interaction with TrpH100. For example, the
galactose (Gal) residue in a Salmonella trisaccharide antigen stacks
against TrpL93 in the complex with Fab Se155-4 (34). In addition,
in the same complex, TrpH33 stacks against the C-6 position in
the 6-deoxy sugar Abequose. The BGA antigen contains GalNAc
and a 6-deoxy monosaccharide (fucose, Fuc), thus a revised dock-
ing experiment was sought that would permit the formation of
such interactions with the aromatic residues in the binding pocket.
Thus, two alternative docking experiments were designed: in the
first, the side-chain torsion angles of TrpH100 were allowed to be
flexible during docking (termed flexible residue docking); while in
the second, TrpH100 was mutated to Ala prior to docking, and then
reverted back to Trp after docking (mutational residue docking).
The docked poses were filtered based on three criteria. First, poses
in which the GalNAc was not located within the binding pocket
were eliminated (Figure 2C). This criterion was adopted based
on the results from two array screenings, which indicated that the
antibody interacts exclusively with the BGA antigens (Tables S2
and S3 in Supplementary Material) and because the only struc-
tural difference between BGA and BGB is the presence of the NAc
moiety in the former. Therefore it was hypothesized that the abil-
ity of the antibody to discriminate between these two antigens
FIGURE 1 | (A) Docked antigen A (green) from preliminary docking
experiments with residues lining the binding pocket (shown in yellow). The
antibody is shown in gray. (B) Residues lining the binding pocket before
(yellow) and after (ice blue) the 50 ns MD simulation. Residues HisL49 and
TrpH100 (shaded rings) form stacking interactions during the course of the
simulation thereby causing the ligand to become unstable.
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FIGURE 2 | Docked complexes of BGA (stick structure) in the scFv
binding site (heavy and light chains shown as solvent accessible
surfaces in cyan and pink, respectively, theTrpH100 surface is shown
in dark blue). (A) The stick structures in green and yellow represent
the best-docked poses from the TrpH100-mutagenesis and the flexible
residue docking approaches, respectively. (B) An example of a docked
pose (red) that was eliminated on the basis of clashes ensuing from
the AlaH100Trp mutation. (C) An example of a docked pose (red) that was
eliminated on the basis of the orientation of the ligand in the binding
pocket.
Table 1 | Comparison of glycosidic torsion angles between
experimentally observed values and average values obtained from
the MD simulations.
(φ1, ϕ1)a (φ2, ϕ2)b
Experimental Theoretical Experimental Theoretical
BGA
trisac-
charide
62°<φ1 <82°,
61°<ϕ1 <74°
−68±14°,
51± 25°
−77°< φ2 <−67°,
−109°< ϕ2 <−86°
−69±11°,
−101±26°
BGA–
scFv
complex
68°, 77° 82±11°,
68±7°
−68°, −90° −69±8°,
−113±10°
aGlycosidic torsion angles for the GalNAcα(1,3)Gal (φ1, ϕ1).
bTorsion angles for Fucα(1,2)Gal (φ2, ϕ2).
would be dependent on interactions with this residue. Second,
in the case of the mutational approach, poses were rejected if
the Ala-Trp mutation led to irreconcilable steric clashes with the
antigen (Figure 2B). All the docked poses obtained from each of
these approaches were then scored using a CHI scoring function.
After applying these criteria, both docking approaches identified
essentially equivalent antigen poses (0.48 Å RMSD between lig-
and positions) (Figure 2A), in which the C-6 atom of the GalNAc
forms a CH/pi stacking interaction with the TrpH96. This complex
was selected for further analysis by MD simulation.
STRUCTURAL STABILITY OF THE IMMUNE COMPLEXES
Blood group A
The final docked model of the blood group antigen A bound to
the antibody remained stable during the course of a 50 ns simu-
lation based on the RMSD of the ring atoms of the ligand, which
remained between 2 and 4 Å over the course of the simulation
(Figure 5). An analysis of the ring conformational preferences
showed that all three residues in the trisaccharide remained in
the 4C1 chair conformations. The φ- and ψ-glycosidic torsion
angles for the GalNAcα(1,3)Gal (φ1, ψ1) and Fucα(1,2)Gal (φ2,
FIGURE 3 | Non-bonded interactions between the BGA and Fab AC1001
[prepared using LigPlot (38)]. The structure represents a single frame of
the MD simulation that is closest to the average RMSD of the structure
during the simulation. Unless shown with an H, all residues are from VL.
ψ2) linkages were monitored throughout both the simulations
(BGA–scFv complex and BGA trisaccharide in solution) and the
average values were found to be in agreement with the values
observed for the same trisaccharide in the complex with Dolichos
biflorus lectin as well as the conformations of the trisaccharide
in solution (35) (Table 1). The stacking interactions between the
GalNAc and TrpH96 interactions were characterized by the angle
(θ) between the normals to the ring planes, and the distance (R)
between their centroids (36). For an ideal stacking conformation,
θ should be around 180° or 0°, and for CH/pi, it should be around
90°. The average θ value was close to the latter at 108° (with a
standard deviation of 9°) at a distance of 6.5 Å.
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FIGURE 4 | (A) The χ2 angle of the HisL49 during the course of the simulation. (B) HisL49 (shown in yellow) during the first 18 ns of the simulation (top) and the
remainder of the simulation (bottom).
Table 2 | Hydrogen bonds between BGA and the scFv during the MD simulation.
Donor Acceptor MD period: 0–18 ns MD period: 18–50 ns
Distancea (Å) Occupancy (%) Distance (Å) Occupancy (%)
GalNAc O3 AsnL34 Hδ1 3.1 (0.18)c 67 >3.5 –
O4 AsnL34 Hδ1 3.1(0.22) 32 3.0 (0.17) 77
O2N HisL49 Hδ >3.5 – 2.9 (0.16) 91
Gal O4 GalNAc H2N 3.2 (0.17) 65 3.2 (0.17) 31
O4 AsnH98 Hδ1 3.1 (0.18) 45 3.1 (0.17) 41
aStandard deviations in parentheses.
During the course of the MD simulation, the side chain of
HisL49 was observed to flip from its initial orientation (χ2=〈-73〉)
to (〈115〉) in which it could form a hydrogen bond with the N-
acetyl group of the GalNAc residue (Figures 3 and 4; Table 2). This
interaction remained stable for the remainder of the 50 ns simula-
tion. This side-chain flip may represent an example of induced fit
during ligand binding, however, at the resolution of the present X-
ray data (2.2 Å), it is not possible to reliably discriminate between
histidine χ2 rotamers (37).
Blood group B
To probe the specificity of the antibody for antigen B, the scFv
was screened experimentally against an array of neoglycocon-
jugates including ABO and related blood group antigens. The
screening confirmed the exclusive specificity of the antibody for
BGA-related antigens (Tables S2 and S3 in Supplementary Mate-
rial). Computational carbohydrate grafting (39) of the relevant
glycans from the array onto the bound BGA trisaccharide in the
scFv complex confirmed that all of the BGA- and BGB-related
glycans could be accommodated in the binding pocket (Table S3
in Supplementary Material). Therefore, the lack of binding of the
BGB-glycans does not appear to be due to steric collisions, but
rather to the loss of affinity arising from the absence of the NAc
group in the BGA congeners. MD simulation of the BGB–scFv
complex was employed to examine the effect of the loss of the NAc
moiety on the stability and affinity of the structural difference in
the antigens on the stability and affinity of the putative immune
complex. Despite the fact that the MD simulations of the two com-
plexes (BGA and BGB) were started with the antigens aligned in
identical binding modes, the BGB antigen dissociated from the
antibody after a relatively short simulation period of 10 ns. In
order to eliminate the possibility that this instability arose due
to artifacts from the conversion of the BGA to BGB antigen, two
additional simulations were performed with independent initial
atomic velocities. In both cases, the ligand appeared to dissoci-
ate from the antibody after approximately 10 ns (Figure 5). To
enable comparison with the BGA complex, only the data from the
initial stable 10 ns period of the BGB complex were chosen for
analysis.
In antigen–scFv complexes, the Gal or GalNAc residues are
flanked by residues TyrL50, AsnL34 and HisL49 on one side of the
antigen (Group 1) and residues TrpH100 and TrpL96 (Group 2)
on the other; the Fuc interacts with GlyL91 and AsnL92 (Group 3)
(Figure 6). In contrast to the case of the BGA antigen, in the
BGB–scFv simulation HisL49 does not form a stabilizing interac-
tion with the terminal Gal residue. Additionally, the Gal and Fucl
residues display enhanced flexibility owing to the loss of stabilizing
interactions with residues from Groups 2 and 3.
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INVOLVEMENT OF HISL49 IN BINDING AFFINITY
All histidines in the scFv were protonated by default for mod-
eling with a hydrogen atom at the δ nitrogen position. During
the MD simulation of the BGA–scFv complex, the χ2 angle of
HisL49 flips (-73° to 115°) enabling a hydrogen bond to form with
the carbonyl moiety of the NAc group in the GalNAc residue in
BGA, which would be expected to be significant for enhancing
the stability of the BGA–scFv complex. In the BGB complex,
the same HisL49 forms an interaction with the non-terminal Gal
residue. The interaction with HisL49 suggests that there might
FIGURE 5 |Time series of the RMSD values for the ring atoms of the
BGA (green) and BGB (from three independent simulations, blue,
purple, and red) antigens, relative to the starting conformation of the
complex.
also be a pH dependence on binding; at lower pH all histidines
would be positively charged, potentially enhancing the strength of
the HisL49–BGA hydrogen bond, leading to higher binding affin-
ity. This prediction was confirmed by BLI measurements, which
showed a marked decrease in the apparent K D as the pH dropped
below the pK a of histidine (Figure 7). It should be noted that
this protonation would not be localized to HisL49 nevertheless, no
enhanced non-specific binding was observed at low pH for either
BSA or BGA–Lex (Figures S1–S3 in Supplementary Material), sup-
porting a role for a direct interaction between HisL49 and the BGA
antigen.
BINDING ENERGY ANALYSIS
A per-residue decomposition of the interaction energies in the
immune complexes indicated that, in the case of BGA, the
FIGURE 7 |The reference (BSA)-subtracted pH dependence of the
apparent K D for the interaction between scFv AC1001 and the
BSA–BGA conjugate. Error bars are derived from replicates of five
measurements. Note, the pK a of histidine is 6.04 (40).
FIGURE 6 | (Left) The antigens are flanked by TyrL50, AsnL34, and HisL49 (Group 1, green surface), and TrpH100 and TrpL96 (Group 2, pink surface). Fuc interacts with
GlyL91 and AsnL92 (Group3, yellow surface). (Right) Atomic fluctuations of residues Gal, GalNAc/Gal (BGA/BGB), and Fuc as a function of time.
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GalNAc residue contributed 25% (-8.1 kcal/mol) toward the bind-
ing energy, compared to a reduced (-4.3 kcal/mol) contribution
from the corresponding Gal residue in BGB (Table 3). This loss
Table 3 | Keya per-residue contributions toward the energy for the
BGA and BGB–scFv complexes.
Residue vdW Electrostatic Polar
desolvation
Non-polar
desolvation
Total
Antibody
TyrL32 −4.2b −1.4 2.1 −0.5 −4.0
−3.0b −1.7 2.0 −0.5 −3.2
GlyL91 −0.8 −4.8 3.2 −0.2 −2.5
– – – – –
TrpH100 −2.5 −1.2 1.7 −0.3 −2.2
−2.8 −1.0 1.2 −0.4 −2.9
TrpL96 −1.4 −1.1 0.7 −0.2 −2.0
−0.7 −0.3 0.2 −0.1 −0.9
AsnL34 −0.8 −1.6 0.9 −0.1 −1.6
−0.6 −3.7 1.5 −0.1 −2.9
AsnH98 −2.2 −2.9 4.0 −0.5 −1.5
−2.8 −1.6 3.8 −0.5 −1.1
AsnL92 −1 −2.9 2.6 −0.2 −1.5
– – – – –
TyrL50 −1.6 −0.9 1.1 −0.1 −1.5
−1.7 −1.0 1.4 −0.1 −1.5
LeuH99 −1.4 −1 1 −0.1 −1.4
−1.4 −0.3 0.8 −0.1 −1
HisL49 −0.6 −3.3 2.5 −0.1 −1.4
−1.3 −2.8 2.5 −0.2 −1.8
ThrL93 −0.5 −0.6 0.6 0.0 −0.5
– – – – –
Subtotal −17.1 −20.5 20.5 −2.2 −19.3
−11.3 −12.4 13.4 −2 −15.3
Antigen
Gal −3.1 −0.4 1.2 −0.4 −2.7
−6.2 −3.7 5.2 −0.9 −5.6
GalNAc/Gal −13.1 −12.5 19.6 −2.1 −8.1
−10.1 −8.2 15.8 −1.7 −4.3
Fuc −4.0 −9.7 12.2 −0.8 −2.3
−2.5 −1.2 4.5 −0.4 0.4
Ligand total −20.2 −22.6 32.9 −3.2 −13.2
−18.9 −13.2 25.4 −1.4 −9.6
aKey residues defined as those that contribute >0.5 kcal/mol to the total interac-
tion energy for either the BGA or BGB in the complexes. Only the initial stable
10 ns period of the BGB simulation was employed, whereas the entire 50 ns
trajectory for BGA was analyzed.
bUpper row, values for BGA; lower, BGB.
of 4 kcal/mol of interaction energy is the predominant difference
between the two antigens, and would be enough to reduce the
affinity by nearly 800-fold, consistent with the lack of appar-
ent binding of the BGB analogs in the glycan array screening.
In addition, this analysis identified the residues that contributed
significantly toward antigen binding.
In the BGA–scFv complex, residues from CDR L3 make the
maximum contributions to binding (GlyL91+TrpL96+AsnL92+
ThrL93= -7.2 kcal/mol) followed by H3 (AsnH98+TrpH100+
LeuH99= -5.5 kcal/mol), L1 (TyrL32+AsnL34= -4.5 kcal/mol),
and L2 (TyrL50= -1.02 kcal/mol). In contrast, in the case of BGB,
the same residues from L3 contribute less than a total of 1 kcal/mol
to the interaction energies. The most significant single residues are
TyrL32, GlyL91, TrpH100, and TrpL96, which each contributes more
than 2 kcal/mol and together account for 50% of the total affin-
ity. Residues GlyL91 and AsnL92 that form hydrogen bonds with
the Fuc residue together contribute -4.0 kcal/mol to the binding
of BGA, but fail to make any stable interactions in the BGB sim-
ulation and therefore contribute negligibly to the affinity. It is
these interactions that provide the predominant contributions to
the preferential binding of the BGA antigen. While in the BGB
complex, HisL49 does not form any stable hydrogen bonds with
the terminal Gal, it is able to form new, albeit transient, interac-
tions with the non-terminal Gal for 30% of the stable simulation
period. Therefore, while the per-residue contribution values indi-
cate that HisL49 makes a contribution greater than -1.5 kcal/mol in
both cases, the interactions it forms in BGA are more stable when
compared to the interactions in BGB.
CONCLUSION
In this study, 3D models of the BGA and BGB trisaccharides
in complex with scFv AC1001 were generated that provided
a detailed atomic level rationalization of the interactions and
dynamics responsible for antigen specificity. Quantification of
the binding affinities identified key residues in the binding site
that are predicted to contribute to specific and non-specific inter-
actions with each antigen and led to the confirmed prediction
of enhanced binding at lower pH. The spontaneous dissociation
of antigen B from the scFv–BGB complexes (in three different
simulations) indicated that MD simulations confirm the known
preference of this antibody for the A antigen, and support a role for
MD simulations in overcoming limitations associated with ligand
docking. The present study illustrates that integration of multi-
ple experimental (affinity measurements, glycan array screening,
and crystallography) and theoretical (ligand docking, MD sim-
ulation, and energy decomposition) methods provides a power-
ful platform for predicting the origin of antibody–carbohydrate
specificity.
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